"Since abdominal hysterectomy is invasive and still the most
common hysterectomy approach, the chances of surgical complications,
such as severe bleeding and infection at the surgery site increase ,
coupled with an extended stay in the hospital," says Frost + Sullivan
Research Analyst S. The foundation of this partnership approach is our Growth
Partnership Services platform, whereby we provide industry research,
marketing strategies, consulting, and training to our clients to help
grow their business. Gross profit for the same period in the
prior year was $4.0 million, or $0. Forward -
looking statements include statements that address activities, events or
developments that AtriCure expects, believes or anticipates will or may occur
in the future, such as earnings estimates, other predictions of financial
performance, launches by AtriCure of new products and market acceptance of
AtriCure's products. These risks and uncertainties include the
rate and degree of market acceptance of AtriCure's products, AtriCure's
ability to develop and market new and enhanced products, the timing of and
ability to obtain and maintain regulatory clearances and approvals for its
products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure's products, competition from existing and new products and
procedures or AtriCure's ability to effectively react to other risks and
uncertainties described from time to time in AtriCure's SEC filings, such as
fluctuation of quarterly financial results, reliance on third party
manufacturers and suppliers, litigation or other proceedings, government
regulation and stock price volatility.

suru nailing

with the 2005 Pelvic Reconstructive
Surgery Technologies Company of the Year Award at tonight's 2nd annual
Excellence in Medical Devices + Healthcare Awards Banquet for
developing and introducing a variety of innovative, minimally
interventional medical procedure kits.
Research and development expenses were $2. A telephonic replay of the call will be available until
March 2, 2006.
AtriCure, Inc.

electrosurgery nailing

S.4 million in worldwide MIS
product revenue. Fourth quarter 2005 revenue from domestic open-heart products
was $5.4 million with a gross
margin of 75.9 million with a gross margin of 74.0%, as compared
to gross profit of $14.3 million for the third quarter of 2005.
Cash, cash equivalents and short-term investments at December 31, 2005
were $33."

Financial Guidance
The Company believes it is currently experiencing a negative impact upon
its business from newspaper articles published in December relating to two
pioneering institutions that have been proponents and investigators of the
Company's products . The replay dial-in numbers are (888) 286-8010 for domestic
callers and (617) 801-6888 for international callers.86) $(2.

stents electrosurgery

Additionally, the uterus is restored to its
correct anatomic position by shortening the round ligaments. The
procedure can also restore support in post-hysterectomy patients using
minimal intervention. The company vision has always been to develop a
straightforward laparoscopic approach that is easy to learn and
perform by surgeons., is a privately
held medical device company that markets specialty laparoscopic
surgical products. For more information about the company, visit
www .frost.4 million for the full year 2004. Selling, general and
administrative expenses for the full year were $24.17)

Weighted average
shares outstanding:
Basic and diluted 12,068,358 1,878,923 6,025,300 1,828,452

(a) Includes the following expenses resulting from transactions with
Enable Medical Corporation prior to the acquisition as of August 10,
2005:

Cost of revenues $-- $1,327,267 $4,259,269 $4,941,341
Research and development
expenses $-- $391 ,641 $1,201,583 $1,228,659

ATRICURE, INC.

weck microvascular

Carter, the UPLIFT procedure
has provided clinical benefit to thousands of women with symptomatic
retroverted uterus .

About Inlet Medical, Inc.S.0 million, a 61.2 million, revenue from domestic minimally invasive sole-therapy
products was $2.8 million for the fourth quarter
2005, compared with $1.

weck endoscope

using the Isolator(TM)
Endoscopic Ablation System

- Enrolled 17 of necessary 25 patients in Restore II clinical trial

Full Year 2005 Highlights

- Total revenue increased 61.6 million, a 49.4%
increase over $5.6% increase over
$19.6 million, compared to
$15.
The Company reported a fourth quarter net loss of $4. We believe our progress in 2005 and ongoing clinical
investigation is positioning our minimally invasive platform to become a
standard treatment alternative for those patients who suffer from atrial
fibrillation. In the wake of these articles , the Company understands
that certain external educational, training, and clinical trial activities
involving its products have diminished. The Isolator(TM) bipolar pen is a sterile, single use device
intended to ablate cardiac tissue during cardiac surgery using radiofrequency
(RF) energy. Use of the Isolator(TM) bipolar pen and Isolator(TM) bipolar
ablation system for the surgical treatment of atrial fibrillation is
investigational and has not been approved by the U.

radiofrequency microvascular

For more
information , visit www.6 million, and expects to provide guidance for the full year of
2006 by the Company's first quarter 2006 earnings conference call.S.

radiofrequency retractors

Frost + Sullivan Names Inlet Medical 2005 Pelvic Reconstructive Surgery Technologies Company of the Year

"
ELEVEST(R) utilizes a minimally interventional laparoscopic
technique to treat uterine prolapse.2 million with a gross margin of 72.5 million for the fourth quarter 2004 and $2. AtriCure does not guarantee any
forward-looking statement, and actual results may differ materially from those
projected.

ATRICURE, INC .10) $(5.

tullytown ethicon

It gives patients a choice and
more control over their own health. In fact, the Society of Laparoendoscopic Surgeons (SLS)
has recognized Inlet's efforts to provide best-in-class surgical
products for the women's health market in 2003 for the ELEVEST(R)
procedure kit and again in 2004 for the Carter-Thomason CloseSure
System XL(TM), used to provide full-thickness closure for laparoscopic
trocar port wounds in obese and bariatric patients.org

About Frost + Sullivan

Frost + Sullivan, a global growth consulting company founded in
1961, partners with clients to create value through innovative growth
strategies.
CONDENSED BALANCE SHEETS
(Unaudited)

December 31, December 31,
2005 2004
Assets

Current assets:
Cash and cash equivalents $27,432,948 $5,175,177
Short-term investments 6,369,234 --
Accounts receivable, less
allowance for doubtful
accounts of $261 ,707 and
$56,779 as of December 31, 2005
and December 31, 2004, respectively 4,865,065 3,520,621
Inventory 2,135,143 1,087,408
Prepaid expenses and other
current assets 845,330 112,740

Total current assets 41,647,720 9,895,946

Property and equipment, net 3,359,549 2,410,051

Deferred offering costs -- 412,005

Intangible assets 986,778 --

Goodwill 3,840,837 --

Other assets 205,531 12,618

Total assets $50,040,415 $12,730,620

Liabilities and shareholders' equity

Current liabilities:
Accounts payable (a) $1,243,365 $733,444
Accrued liabilities 4,131,633 2,572,329
Current maturities of capital
lease obligation 31,753 --
Current maturities of long-term debt 366,207 --

Total current liabilities 5,772,958 3,305,773

Capital lease obligation 38,855 --

Long-term debt 1,045,150 --

Redeemable preferred stock:
Preferred stock, $0.

electrosurgery hygenic

It shortens and
strengthens the uterosacral ligaments to support the vagina and may be
performed concurrently at the time of laparoscopic hysterectomy., Frost + Sullivan's 2005 Excellence
in Medical Devices + Healthcare Awards Banquet honors world-class
companies for outstanding performance and achievements in the medical
industry.

About AtriCure, Inc.001 par value,
90,000,000 and 10,526,315
shares authorized as of
December 31, 2005 and
December 31, 2004, respectively;
12,086,482 and 1,880,169 issued and
outstanding as of December
31, 2005 and December 31,
2004, respectively 12,086 1,880
Additional paid-in capital 86,107,520 3,281,447
Unearned compensation (599,591) (981,612)
Other comprehensive income 826 --
Accumulated deficit (42 ,337,389) (29,633,009)

Total shareholders' equity
(deficit ) 43,183,452 (27,331,294)

Total liabilities and shareholders '
equity $50,040,415 $12,730,620

(a) Includes the following liabilities resulting from transactions with
Enable Medical Corporation prior to the acquisition as of August 10,
2005:

Accounts payable $-- $434,869

ATRICURE, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)

Year Ended December 31,
2005 2004

Cash flows from operating activities:
Net loss $(12,682,964) $(9,451,868)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 1,554,238 962,355
Loss on disposal of equipment 36,813 16,561
Write-off of tooling 266,195 --
Stock compensation 673,199 1,014,204
Preferred stock interest 2,332,254 3,905,169
Changes in assets and liabilities:
Accounts receivable 92,432 (1,892,795)
Inventory (193,559) (448,413)
Prepaid expenses and other
current assets (709,880) 97,482
Other assets (a) 409,985 (417,453)
Accounts payable 27,911 454,730
Accrued liabilities (a) 577,467 1,959,957

Net cash used in
operating activities (7,615,909) (3,800,071)

Cash flows from investing activities:
Purchases of property + equipment (1,951,733) (1,513,273)
Purchases of available-for-sale
securities (6,368,408 ) --
Cash paid for acquisition, net (6,420,681) --

Net cash used in
investing activities (14,740,822 ) (1,513,273)

Cash flow from financing activities:
Proceeds from long-term debt borrowings 1,500,000 --
Payments on long-term debt (88,643) --
Payments on capital lease obligations (16,063) --
Proceeds from stock offering 43,176,994 --
Proceeds from stock option
exercise and warrants 42,214 89,183

Net cash provided by
financing activities 44,614,502 89,183

Net increase (decrease) in cash and
cash equivalents 22,257,771 (5,224,161)
Cash and cash equivalents - beginning
of period 5,175,177 10,399,338

Cash and cash equivalents - end of
period $27,432,948 $5,175 ,177

(a) Cash flows from operating activities excludes non-cash costs related
to the initial public offering in other assets and accrued liabilities

Contacts:

AtriCure, Inc.

scalpel stents

AVESTA(R) simplifies the process of suturing,
making it easier and quicker for surgeons to reattach/shorten the
uterosacral ligaments.
Another of Inlet Medical's innovative products is the Metra PS(R)
procedure kit, which is designed to perform the UPLIFT procedure
(Uterine Positioning by Ligament Investment Fixation and Truncation). To accomplish its developmental goals, Inlet
Medical has placed strong emphasis on research and technology
development., based in Eden Prairie, Minn.inletmedical.0%

- Performed first human cases in the U.
Fourth quarter 2005 consolidated revenue was $8.6 million
for the third quarter 2005.2 million for the full year 2004.33
per share.8 million.atricure. Medical journals have described the
adoption by leading cardiothoracic surgeons of the AtriCure, Inc. AtriCure undertakes no obligation to publicly update any forward-
looking statement, whether as a result of new information, future events or
otherwise .

microsurgery galia

Inlet Medical's procedure kits include ELEVEST(R), AVESTA(R), and
Metra PS(R) -- all laparoscopic approaches to treat female pelvic
support problems.1 million and domestic revenue from the bipolar pen and other
revenue was $0.
The year-over-year and quarter-over-quarter increases were attributable
primarily to the recruitment of additional full-time engineers and the
expansion of product development initiatives and clinical trials.

ethicon postoperative

"Inlet Medical's ELEVEST(R)
procedure offers women a minimally invasive , outpatient procedure as
an alternative to hysterectomy, provides physicians with another
procedure to differentiate their practice, and expands previously
limited treatment options for patients. A key benefit that Frost + Sullivan brings to its
clients is a global perspective on a broad range of industries,
markets, technologies, econometrics, and demographics.4 million

- Launched Isolator(TM) bipolar pen with cardiac tissue indication

- Completed IPO raising $43 million in net proceeds

- Acquired supply partner Enable Medical

WEST CHESTER, Ohio, AtriCure, Inc.0 million with a gross margin of 72.0
million to $8.

Conference Call
AtriCure will host a Web cast and conference call at 9:00 am ET on
February 17, 2006 to discuss fourth quarter 2005 results. bipolar
ablation system as a standard treatment alternative during open -heart surgical
procedures to safely, rapidly and reliably create lesions in cardiac, or
heart , tissue to block the abnormal electrical impulses that cause atrial
fibrillation, a rapid, irregular quivering of the upper chambers of the heart.

sutures postoperative

Other well-known products from the company include
the Carter-Thomason CloseSure(R) System and the Carter-Thomason
CloseSure System XL(TM) for laparoscopic port site closure. James E.inletmedical.6% to $31.0 million

- First full-year worldwide MIS product revenue of $6. Full year
2005 consolidated revenue was $31. For the full year
2005 , gross profit was $22.
Selling, general and administrative expenses were $7. The dial-in
numbers are (866) 356-3093 for domestic callers, and (617) 597-5381 for
international callers.com
nlaudico@theruthgroup.

fixation visx

While
hysterectomy has been the most often used treatment for uterine
prolapse , there are several concerns, such as vaginal vault prolapse
and other long-term side effects related to the use of this procedure.4%
sequential increase over $7. The year-over-year and quarter-over -quarter increases to gross
margin are primarily the result of new product launches, such as the
Isolator (TM) bipolar pen and Isolator(TM) Long products, and the third quarter
acquisition of Enable Medical . is a medical device company focused on developing,
manufacturing and selling innovative surgical devices to create precise
lesions, or scars, in soft tissues. Food and Drug
Administration.com

microvascular sutures

It recognizes
exceptional customer service and the ability to combine technology and
successful strategic initiatives to take advantage of market changes
within the existing competitive landscape . It develops and markets laparoscopic surgical
instruments to laparoscopic surgeons and to gynecologists who perform
pelvic reconstructive surgery in women.

nailing sutures

Pioneered in the 1990s by Dr.
Held in San Francisco, Calif. Each year there are more than two
million laparoscopic procedures in the U.com

International revenue for the fourth quarter of 2005
was $0.1 million, compared to $4 .4% for the fourth quarter and 61.001 par
value; designated Series A,
2,182 ,521 shares authorized,
issued and outstanding as of
December 31, 2004 -- 7,979,396
Preferred stock, $0.

scalpel gauze

Fourth Quarter 2005 Highlights

- Total revenue increased 49.6 million

- Gross margin increased 230 basis points to 75.2 million for the full year 2004, including $6. During the
year, we saw substantial penetration of our products in the open-heart market
and made considerable strides towards establishing our minimally invasive
sole-therapy platform.

retractors postoperative

For its efforts in developing innovative, viable solutions for
under-recognized, under-treated, and unmet health issues for women and
in developing medical procedures that serve as viable alternatives to
treat the associated medical problems, Inlet Medical is a worthy
recipient of Frost + Sullivan's 2005 Pelvic Reconstructive Surgery
Technologies Company of the Year Award.2 million for the third quarter of 2005.

galia fixation

The
laparoscopic technique leads to reduced hospital stay and fewer
surgical complications. With a client
list that includes Global 1000 companies, emerging companies, as well
as the investment community, Frost + Sullivan has evolved into one of
the premier growth consulting companies in the world.
(Nasdaq: ATRC), a medical device company focused on developing, manufacturing
and selling innovative surgical devices, announced today financial results for
the fourth quarter and full year ended December 31, 2005.
David Drachman , President and Chief Executive Officer, said, "We are
extremely pleased with our fourth quarter and full year results. Our revenue
growth of 49. A live Web cast of
the conference call will be available online from the investor relations page
of AtriCure's corporate Web site at http://www. The reservation number for both is 94539581.

sutures electrosurgical

Uterine prolapse, a major health concern for women, affects
approximately three million American women annually. Ravi Shankar. An annual event, the banquet recognizes the quality and
merit of distinguished individuals and companies.7 million.
Gross profit for the fourth quarter 2005 was $6.0%, including a $266,000 write-off related to production
equipment for discontinued products. Research and development expenses for the full
year 2005 were $9.6% for the full year reflects
our leadership position in the surgical treatment of atrial fibrillation based
on the adoption of our products by leading cardiothoracic surgeons. A
recording of the conference call will remain available on AtriCure's Web site
through May 18, 2006.

stents gauze

In this procedure, the
uterosacral ligaments are strengthened and shortened to support the
uterus in the pelvis.
To address the problem of vaginal vault prolapse that occurs in up
to 25 percent of the patients who have undergone hysterectomy , Inlet
Medical developed the AVESTA(R) procedure kit.
Inlet Medicals' innovative solutions have essentially changed the
way in which women and surgeons look at female pelvic support
problems .com. Educational information about the procedures is
available at www. Please use reservation
code 59820347.

This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.com

Jason Rando (media)
(646) 536-7025
jrando@theruthgroup .

rtech sodem

Business Editors/Health/Medical Writers

SAN FRANCISCO----Frost + Sullivan
will present Inlet Medical, Inc.
Moreover, removal of the uterus prevents conception, often making
hysterectomy unappealing to patients who are still in their
reproductive years. The
procedure obviates the need for hysterectomy and is particularly
useful to patients who want to maintain their fertility and for those
who want a less invasive technique to treat uterine prolapse.4% to $8.6 million.7% .8% for the full
year 2004.2 million for the fourth quarter of 2004
and $6. The year-over-year and quarter-over-
quarter increases were attributable primarily to the expansion of the sales
and marketing organization, the establishment of a European subsidiary and an
increase in expenses associated with being a public company.

hygenic sarel

Frost + Sullivan presents its Company of the Year Award to a
company that has demonstrated outstanding management, consistent
growth, and positive social/economic impact on local and national
communities and customers within its industry. for which the
Carter-Thomason CloseSure(R) System can be used for full-thickness
trocar wound closure.

AtriCure Reports Fourth Quarter and Full Year 2005 Financial Results

7 million for the fourth quarter of 2004 and a 19.9 million for the
fourth quarter 2005, compared with $5. We expect our RESTORE-II clinical trial will provide evidence
to stimulate the broad adoption of our MIS platform. While AtriCure continues to evaluate
and monitor the effects of these developments on its business, the Company
currently estimates revenue for the first quarter of 2006 will range from $8.com.001 par
value; designated Series B,
4,059,720 shares authorized;
3,829,499 issued and outstanding
as of December 31, 2004 -- 28,776,745

Total redeemable preferred stock -- 36,756,141

Shareholders' equity (deficit ):
Common stock, $0.

thermotherapy ethicon

Inlet Medical, Inc. As many as five million women
in the United States may be able to benefit from the company's unique
women's health product offerings.
The Isolator(TM) bipolar ablation system is composed of a radiofrequency
ASU generator and a sterile , single use device intended to ablate soft tissue
during Thoracic, General, ENT, Gynecological and Urological surgical
procedures. Forward-looking statements are based on AtriCure's
experience and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many of
which are beyond AtriCure's control.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

Three Months Ended Year Ended
December 31, December 31,
2005 2004 2005 2004
Revenues $8,559,060 $5,730,262 $30,956,987 $19,157,032
Cost of revenues (a) 2,143,581 1 ,564,435 8,056,680 5,201,562

Gross profit 6,415,479 4,165,827 22,900 ,307 13,955,470

Operating expenses:
Research and
development
expenses (a) 2,788,229 1,503,636 9,108,600 4,422,014
Selling, general
and administrative
expenses 7,923,639 5,197,677 24,594,489 15,169,157

Total
operating
expenses 10,711,868 6,701,313 33,703,089 19,591,171

Loss from operations (4,296,389) (2,535,486) (10,802,782) (5,635,701)
Preferred stock
interest expense -- (976,293 ) (2,332,254) (3,905,169)
Other interest income
(expense), net 291,584 25,901 414,136 105,926
Other income -- -- 84 ,868 --

Loss before income
taxes (4,004,805) (3,485,878 ) (12,636,032) (9,434,944)
Income tax expense (4,707) 48 (46,932) (16,924)

Net loss available to
common shareholders $(4,009,512) $(3,485,830) $ (12,682,964) $(9,451,868)

Basic and diluted
loss per share $(0.33) $(1. The Ruth Group
Thomas Etergino Stephanie Carrington / Nick Laudico (investors)
Chief Financial Officer (646) 536-7017 / 7030
513-755-4561 scarrington@theruthgroup.